Spire Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.8K | Sell |
118
-76
| -39% | -$9.55K | ﹤0.01% | 1602 |
|
|
2025
Q1 | $21.5K | Sell |
194
-2
| -1% | -$221 | ﹤0.01% | 1588 |
|
|
2024
Q4 | $26.8K | Sell |
196
-2
| -1% | -$273 | ﹤0.01% | 1523 |
|
|
2024
Q3 | $22.8K | Hold |
198
| – | – | ﹤0.01% | 1403 |
|
|
2024
Q2 | $27.3K | Buy |
198
+62
| +46% | +$8.54K | ﹤0.01% | 1326 |
|
|
2024
Q1 | $18.8K | Sell |
136
-17
| -11% | -$2.35K | ﹤0.01% | 1536 |
|
|
2023
Q4 | $21K | Buy |
153
+80
| +110% | +$11K | ﹤0.01% | 1526 |
|
|
2023
Q3 | $8.21K | Sell |
73
-316
| -81% | -$35.6K | ﹤0.01% | 1785 |
|
|
2023
Q2 | $36.7K | Buy |
389
+10
| +3% | +$943 | ﹤0.01% | 1340 |
|
|
2023
Q1 | $38.4K | Buy |
379
+254
| +203% | +$25.7K | ﹤0.01% | 1315 |
|
|
2022
Q4 | $15K | Buy |
125
+15
| +14% | +$1.8K | ﹤0.01% | 1481 |
|
|
2022
Q3 | $12K | Sell |
110
-5
| -4% | -$545 | ﹤0.01% | 1509 |
|
|
2022
Q2 | $11K | Buy |
115
+5
| +5% | +$478 | ﹤0.01% | 1887 |
|
|
2022
Q1 | $10K | Sell |
110
-17
| -13% | -$1.55K | ﹤0.01% | 2037 |
|
|
2021
Q4 | $11K | Sell |
127
-183
| -59% | -$15.9K | ﹤0.01% | 2349 |
|
|
2021
Q3 | $30K | Hold |
310
| – | – | ﹤0.01% | 1689 |
|
|
2021
Q2 | $30K | Sell |
310
-283
| -48% | -$27.4K | ﹤0.01% | 1707 |
|
|
2021
Q1 | $58K | Buy |
+593
| New | +$58K | ﹤0.01% | 1653 |
|